

L1: Introduction to Nanomedicines

David Clarke

Professor of Drug Delivery, University of Manchester, UK
david.clarke@manchester.ac.uk

**Lecture Series at the
Institute of Chemical Biology & Fundamental Medicine
for Siberian Branch of Russian Academy of Sciences**


Please do not reproduce & disseminate in breach of © Copyright material included.

Intended Learning Outcomes

To be aware of the wide range nanomedicines and to understand the principles underlying their different behaviours in the body, which are developed in more detail:


- L2 as diagnostic contrast agents
- L3-4 at epithelial barriers (gut, skin & lung RoAs)
- L5-6 as reasons for success of biologics & nanoparticles
- L7-8 for overcoming membrane barriers & targeting
- L9-10 for overcoming drug-resistant infections
(Moscow: RNA targeting for different diseases)

Nano size scales & Nanomedicines




© British Society for Nanomedicine


Nanomedicines: targeted therapeutics



© Chem Soc Rev (2012) 41: 2971–3010




(a) Global nanomedicine market size (USD billions)




(b) Anticancer products market size (USD billions)

© J Drug Delivery (2012) doi:10.1155/2012/38948

Why size is important – PK & biodistribution: particle sizes and delivery barriers




Fate of nanoparticles in the body: size, charge, hydrophobicity




©
McNeil (2009), Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 1:264-271.
Nel et al. (2009), Nature Materials 8: 543-557.
Cover of Advanced Drug Delivery Reviews, June, 2009.

Smaller scale nanomedicines




Larger scale nanomedicine



© J Funct Biomater (2015) 6(2): 277–298


Liposome for Drug Delivery



Lipid self-assembly structures


Critical packing parameter: $P = V / (a \cdot l)$

[V = tail volume, l = tail length, a = area at interface]



© ACS Nano 2017, 11, 7572–7586


Ionizable cationic lipid liposome NPs (LNP)



© ACS Nano 2017, 11, 7572–7586


Ionizable cationic lipids

- Less toxic ionizable lipids
- Cationic lipids interact with endosome anionic lipids
- Endosome acidification increases ionization & interaction
- Endosomal escape




© ACS Nano 2017, 11, 7572–7586

Amphiphile shape, assembly & curvature



Liposome: packing & stabilisation



Vesicle physical stability also increased by


- high phase transition temperature lipids
- polymer-supported lipids (lipid membrane-coated particles)
- lipid-like polymer vesicles (polymersomes)

Liposome stabilisation against disruption by serum proteins

Serum high density lipoproteins (HDL) bind lipids, particularly from less rigid or unstable liposomes, leading to their disintegration, releasing drugs too soon.

Lipid compositions increasing physical rigidity and stability:

high gel-liquid transition temperature (T_c) lipids




high cholesterol, high saturation, longer alkyl chains

dipalmitoyl phosphatidylcholine (DPPC): gel $<33^{\circ}\text{C}$ – fluid $>42^{\circ}\text{C}$

sphingomyelin, ceramide

perfluoroalkylated phospholipids (eg lung aerosol delivery)

Polymersome: structure & stability




© Ann Rev Biomed Eng 8:323–41

Hydrophilic fraction (f) \rightarrow morphology, whereas MW \rightarrow thickness.

Stability increases with membrane thickness to limit set by elasticity (γ).

Water permeation through polymersome membranes considerably reduced compared with phospholipid liposome membranes.

Natural vesicles made from cells



L2: Near patient diagnostics & imaging

Intended Learning Outcomes

- To be aware of how nanotechnology is advancing near patient or point of care (POC) diagnostics (Dx) and body imaging technologies
- To understand how different types of nanoparticles & related nanostructures on surfaces make very small signals bright enough to see

Scope

The science, technology & practice of diagnostics and imaging are considerable – much greater than pharmaceuticals.

***In vitro* diagnostics:**

- **Consumer Dx**
- **Point of care Dx**
- **Drug monitoring**
- **Biomarkers**
- Bioimaging
- Laboratory analysers

***In vivo* diagnostics:**

- Implanted sensors
- Worn sensors
- **Portable imaging**
- **Whole body imaging**

What does Nano do for diagnostics?

- Diagnostics (Dx) often face challenges much greater than *'finding a needle in a hay stack'*
- Few analytes in the body are at sufficient levels to see directly, when lost in the large range of similar compounds or high levels of materials in the body

Nanoscience used to make capture and contrast agents, often using nanoparticle assemblies:


- Capture agents - grab the analyte, so sufficient to see or recover from a sample to measure
- Contrast agents - light up the analyte, so that remote measurements (*eg* imaging scanners) can see it

Dx NPs similar or more advanced than pharmaceutical NPs


IVD: consumer, point of care Dx – some examples

- Magnetic nanoparticles
- Miniaturized NMR
- Gold nanoparticles
- Semiconductor nanoparticles – quantum dots
- Biosensors
- Surface plasmon resonance
- Nanosight
- Photoacoustic


Example: (para)magnetic particles



Magnetism




Miniaturised NMR using rare earth magnets with paramagnetic NPs




© J Biological Eng 2014

Gold / Au NPs


Lateral Flow Assay Architecture




Semiconductor Nanaoparticles “quantum dots / QD”



Example: biosensors




Example: surface plasmon resonance (SPR) sensor and NP sensors




© Med Chem Commun 2014

Nanosight

(making nano visible to a simple camera)



Photoacoustic sensor




Diagnostic imaging & NPs

Imaging using nanoparticles as selective and highly-visible contrast agents:

- Magnetic resonance imaging (MRI)
- Positron emission tomography (PET)
- Photoacoustic
- Raman
- Fluorescence
- Multi-modal imaging (combining above)
- Theranostic : Dx \rightarrow Rx targeted therapy

MRI scanner



Water dominates the relatively-low B magnetic field of the NMR in MRI unless paramagnetic image contrast NPs used, which change the relaxation time (T)

MRI image contrast: biodistribution strongly affected by size

T1 relaxation –bright (+ve) contrast

- Gd chelated to minimize its toxicity

T2 relaxation – dark (-ve) contrast




- iron oxide dextran NPs
- superparamagnetic NPs

Dual - T1 MnFe_2O_4 & T2 $\text{Gd}_2\text{O}(\text{CO}_3)_2$


- minimizes artefacts

Liposomes


- versatility - T1 & T2
- targeting




© Int J Nanomed (2015) 10: 1727-41




Photoacoustic scanning imaging



Raman & fluor scanning imaging



Surface enhanced Raman scattering (SERS)



Raman scattering signals are weak but increased by orders of magnitude for molecules in plasmon resonance field between nanoparticles or on roughened surfaces or at probe tips

NPs in multimodal laser scanning imaging

